Tag: PSMA Theranostic Kits Market Growth

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Through 2030?

The prostate-specific membrane antigen (psma) theranostic kits market has observed swift growth in recent years. This market is expected to increase from $1.05 billion in 2025 to $1.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.9%. The expansion witnessed in the past can be attributed to factors such as the increasing occurrence of prostate cancer, progress in nuclear medicine imaging techniques, greater acceptance of molecular diagnostics, initial successful clinical validation of psma targeting, and the broadening of oncology research initiatives.

The market for prostate-specific membrane antigen (psma) theranostic kits is projected to experience substantial expansion over the coming years. By 2030, its value is anticipated to reach $1.99 billion, progressing at a compound annual growth rate (CAGR) of 13.5%. This growth during the forecast period is driven by factors such as the increasing need for individualized cancer treatments, growing investments in theranostics, the development of nuclear medicine infrastructure, the expanding application of precision oncology diagnostics, and a rise in regulatory approvals for targeted therapies. Key developments anticipated in this period include the wider adoption of targeted radioligand therapies, increased utilization of psma-based precision diagnostics, greater merging of imaging and therapy processes, the proliferation of personalized oncology treatment kits, and a sharpened emphasis on companion diagnostics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30362&type=smp

What Important Drivers Are Powering The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Growth?

The increased occurrence of prostate cancer is anticipated to fuel the expansion of the prostate-specific membrane antigen (PSMA) theranostic kits market moving ahead. Prostate cancer is defined as a malignancy forming in the prostate gland, a small male gland situated beneath the bladder and anterior to the rectum. This growing prevalence is linked to an aging population, given that the likelihood of developing prostate cancer rises considerably with advancing age. Prostate-specific membrane antigen (PSMA) theranostic kits improve the management of prostate cancer by providing targeted diagnostic approaches, which are highly effective for early identification and tailored therapy planning. These kits boost diagnostic precision through the integration of PSMA-specific ligands and radiotracers, thereby facilitating superior disease surveillance and therapeutic direction. As an illustration, in November 2023, the American Cancer Society, a US-based non-profit organization, projected around 313,780 new cases of prostate cancer and 35,770 deaths in the United States by 2025. Consequently, the increasing incidence of prostate cancer is propelling the expansion of the prostate-specific membrane antigen (PSMA) theranostic kits market.

What Segment Categories Are Evaluated In The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Study?

The prostate-specific membrane antigen (psma) theranostic kits market covered in this report is segmented –

1) By Product Type: Diagnostic Kits, Therapeutic Kits, Combined Theranostic Kits

2) By Application: Prostate Cancer, Other Cancers

3) By End-User: Hospitals, Diagnostic Centers, Research Institutes, Specialty Clinics, Other End-Users

Subsegments:

1) By Diagnostic Kits: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography Imaging Kits, Single Photon Emission Computed Tomography Imaging Kits, Companion Diagnostic Kits, Liquid Biopsy Kits

2) By Therapeutic Kits: Radioligand Therapy Kits, Antibody-Based Therapy Kits, Peptide-Based Therapy Kits, Small Molecule Therapy Kits

3) By Combined Theranostic Kits: Integrated Imaging And Therapy Kits, Dual Function Radiopharmaceutical Kits, Prostate-Specific Membrane Antigen (PSMA) Ligand-Based Theranostic Kits, Personalized Treatment Kits

What Trends Are Influencing The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

Leading companies active in the prostate-specific antigen (PSA) test market are prioritizing product development and new launches, including home testing kits for prostate-specific antigen (PSA), to maintain their competitive standing. Home testing kits are self-administered diagnostic tools designed to allow individuals to gather samples, perform tests, and obtain results without needing to visit a healthcare facility. For instance, in September 2023, Randox, an Ireland-based health and toxicology company, unveiled an at-home testing kit for prostate-specific antigen (PSA). The PSA home test aims to measure the levels of PSA in the blood, thereby indicating potential abnormalities within the prostate. PSA is a protein produced by prostate gland cells, and elevated levels can signal various conditions, such as an enlarged prostate, prostatitis, or a urinary tract infection, alongside the possible presence of prostate cancer.

Which Firms Are Competing In The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

Major companies operating in the prostate-specific membrane antigen (psma) theranostic kits market are Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, AdvanCell Pty Ltd, Alpha-9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, RadioMedix Inc., Scintomics GmbH, Novartis AG, Bayer AG, POINT Biopharma Inc., Blue Earth Diagnostics

Access The Complete Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report:

https://www.thebusinessresearchcompany.com/report/global-prostate-specific-membrane-antigen-psma-theranostic-kits-market-report

Which Region Is The Primary Market For The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

North America was the largest region in the prostate-specific membrane antigen (PSMA) theranostic kits market in 2025. The regions covered in the prostate-specific membrane antigen (psma) theranostic kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=30362&type=smp

Browse Through More Reports Similar to the Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market 2026, By The Business Research Company

Prostate Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Endocrine Peptide Test Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market In 2026 And 2030?

The market size for prostate-specific membrane antigen (psma) theranostic kits has experienced rapid expansion in recent years. This market is anticipated to climb from $1.05 billion in 2025 to $1.19 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.9%. The historical growth trajectory can be attributed to several factors including the rising incidence of prostate cancer, notable advancements in nuclear medicine imaging, an increasing embrace of molecular diagnostics, the early successful clinical validation of psma targeting methods, and the ongoing expansion of oncology research programs.

The market for prostate-specific membrane antigen (psma) theranostic kits is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $1.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. This projected growth during the forecast period can be attributed to several factors, including a heightened demand for customized cancer therapies, increased capital expenditure in theranostics, the expansion of nuclear medicine facilities, the expanding application of precision oncology diagnostics, and a rise in regulatory clearances for specific therapies. Key developments expected during the forecast period encompass a greater acceptance of targeted radioligand treatments, an increase in the utilization of psma-based precision diagnostics, a deeper integration of imaging and therapeutic processes, the proliferation of personalized oncology treatment kits, and a strengthened emphasis on companion diagnostics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30362&type=smp

Which Factors Are Influencing The Growth Of The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

An increasing occurrence of prostate cancer is projected to fuel the expansion of the prostate-specific membrane antigen (PSMA) theranostic kits market moving ahead. Prostate cancer is defined as a malignancy that forms within the prostate gland, which is a small gland situated in men beneath the bladder and anterior to the rectum. The growing occurrence of prostate cancer stems from an aging demographic, given that the likelihood of developing this cancer substantially rises with advancing age. Prostate-specific membrane antigen (PSMA) theranostic kits improve prostate cancer management by providing targeted diagnostic options, which makes them highly suitable for prompt detection and customized treatment strategies. These kits boost diagnostic precision through the combination of PSMA-specific ligands and radiotracers, thereby aiding more effective disease tracking and therapeutic direction. For example, in November 2023, estimates from the American Cancer Society, a US-based non-profit organization, indicated approximately 313,780 new prostate cancer cases and 35,770 related deaths were anticipated in the United States by 2025. Consequently, the increasing prevalence of prostate cancer is fueling the expansion of the prostate-specific membrane antigen (PSMA) theranostic kits market.

Which Segments Define The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Segment Structure?

The prostate-specific membrane antigen (psma) theranostic kits market covered in this report is segmented –

1) By Product Type: Diagnostic Kits, Therapeutic Kits, Combined Theranostic Kits

2) By Application: Prostate Cancer, Other Cancers

3) By End-User: Hospitals, Diagnostic Centers, Research Institutes, Specialty Clinics, Other End-Users

Subsegments:

1) By Diagnostic Kits: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography Imaging Kits, Single Photon Emission Computed Tomography Imaging Kits, Companion Diagnostic Kits, Liquid Biopsy Kits

2) By Therapeutic Kits: Radioligand Therapy Kits, Antibody-Based Therapy Kits, Peptide-Based Therapy Kits, Small Molecule Therapy Kits

3) By Combined Theranostic Kits: Integrated Imaging And Therapy Kits, Dual Function Radiopharmaceutical Kits, Prostate-Specific Membrane Antigen (PSMA) Ligand-Based Theranostic Kits, Personalized Treatment Kits

Which Trends Are Influencing Demand In The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

Leading companies within the prostate-specific membrane antigen (PSMA) theranostic kits market are concentrating on developing innovative solutions, such as PSMA-targeted radioligand kits, to address the increasing need for precision oncology, targeted prostate cancer diagnosis, and treatment. PSMA-targeted radioligand kits are medical devices that combine a ligand specifically engineered to bind to Prostate-Specific Membrane Antigen (PSMA) with a radioactive isotope, utilized for either diagnostic imaging or focused therapy of prostate cancer. For instance, in March 2025, Telix Pharmaceuticals Limited, an Australia-based radiopharmaceutical company, launched Illuccix, an advanced kit designed for the preparation of Gallium-68 gozetotide injection. This kit empowers hospitals and nuclear medicine facilities to label the radionuclide immediately before administration for PET imaging of PSMA-positive prostate cancer lesions. Distinctive features of the kit include a ready-to-use preparation format, disease-specific targeting, rapid imaging capabilities, and compatibility with theranostic workflows, which facilitates improved detection of metastatic lesions, comprehensive treatment planning, and effective monitoring of therapy response. Its applications involve diagnosing recurrent or metastatic prostate cancer and guiding personalized treatment decisions, marking a substantial progression over conventional imaging or non-targeted therapies.

Who Are The Established Players Within The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

Major companies operating in the prostate-specific membrane antigen (psma) theranostic kits market are Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, AdvanCell Pty Ltd, Alpha-9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, RadioMedix Inc., Scintomics GmbH, Novartis AG, Bayer AG, POINT Biopharma Inc., Blue Earth Diagnostics

Get The Full Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report:

https://www.thebusinessresearchcompany.com/report/global-prostate-specific-membrane-antigen-psma-theranostic-kits-market-report

Which Region Accounts For The Largest Portion Of The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

North America was the largest region in the prostate-specific membrane antigen (PSMA) theranostic kits market in 2025. The regions covered in the prostate-specific membrane antigen (psma) theranostic kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/global-prostate-specific-membrane-antigen-psma-theranostic-kits-market-report

Browse Through More Reports Similar to the Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market 2026, By The Business Research Company

Prostate Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Endocrine Peptide Test Market Report

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market In 2026 And 2030?

The market size for prostate-specific membrane antigen (psma) theranostic kits has experienced rapid expansion in recent years. This market is anticipated to climb from $1.05 billion in 2025 to $1.19 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.9%. The historical growth trajectory can be attributed to several factors including the rising incidence of prostate cancer, notable advancements in nuclear medicine imaging, an increasing embrace of molecular diagnostics, the early successful clinical validation of psma targeting methods, and the ongoing expansion of oncology research programs.

The market for prostate-specific membrane antigen (psma) theranostic kits is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $1.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. This projected growth during the forecast period can be attributed to several factors, including a heightened demand for customized cancer therapies, increased capital expenditure in theranostics, the expansion of nuclear medicine facilities, the expanding application of precision oncology diagnostics, and a rise in regulatory clearances for specific therapies. Key developments expected during the forecast period encompass a greater acceptance of targeted radioligand treatments, an increase in the utilization of psma-based precision diagnostics, a deeper integration of imaging and therapeutic processes, the proliferation of personalized oncology treatment kits, and a strengthened emphasis on companion diagnostics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30362&type=smp

Which Factors Are Influencing The Growth Of The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

An increasing occurrence of prostate cancer is projected to fuel the expansion of the prostate-specific membrane antigen (PSMA) theranostic kits market moving ahead. Prostate cancer is defined as a malignancy that forms within the prostate gland, which is a small gland situated in men beneath the bladder and anterior to the rectum. The growing occurrence of prostate cancer stems from an aging demographic, given that the likelihood of developing this cancer substantially rises with advancing age. Prostate-specific membrane antigen (PSMA) theranostic kits improve prostate cancer management by providing targeted diagnostic options, which makes them highly suitable for prompt detection and customized treatment strategies. These kits boost diagnostic precision through the combination of PSMA-specific ligands and radiotracers, thereby aiding more effective disease tracking and therapeutic direction. For example, in November 2023, estimates from the American Cancer Society, a US-based non-profit organization, indicated approximately 313,780 new prostate cancer cases and 35,770 related deaths were anticipated in the United States by 2025. Consequently, the increasing prevalence of prostate cancer is fueling the expansion of the prostate-specific membrane antigen (PSMA) theranostic kits market.

Which Segments Define The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Segment Structure?

The prostate-specific membrane antigen (psma) theranostic kits market covered in this report is segmented –

1) By Product Type: Diagnostic Kits, Therapeutic Kits, Combined Theranostic Kits

2) By Application: Prostate Cancer, Other Cancers

3) By End-User: Hospitals, Diagnostic Centers, Research Institutes, Specialty Clinics, Other End-Users

Subsegments:

1) By Diagnostic Kits: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography Imaging Kits, Single Photon Emission Computed Tomography Imaging Kits, Companion Diagnostic Kits, Liquid Biopsy Kits

2) By Therapeutic Kits: Radioligand Therapy Kits, Antibody-Based Therapy Kits, Peptide-Based Therapy Kits, Small Molecule Therapy Kits

3) By Combined Theranostic Kits: Integrated Imaging And Therapy Kits, Dual Function Radiopharmaceutical Kits, Prostate-Specific Membrane Antigen (PSMA) Ligand-Based Theranostic Kits, Personalized Treatment Kits

Which Trends Are Influencing Demand In The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

Leading companies within the prostate-specific membrane antigen (PSMA) theranostic kits market are concentrating on developing innovative solutions, such as PSMA-targeted radioligand kits, to address the increasing need for precision oncology, targeted prostate cancer diagnosis, and treatment. PSMA-targeted radioligand kits are medical devices that combine a ligand specifically engineered to bind to Prostate-Specific Membrane Antigen (PSMA) with a radioactive isotope, utilized for either diagnostic imaging or focused therapy of prostate cancer. For instance, in March 2025, Telix Pharmaceuticals Limited, an Australia-based radiopharmaceutical company, launched Illuccix, an advanced kit designed for the preparation of Gallium-68 gozetotide injection. This kit empowers hospitals and nuclear medicine facilities to label the radionuclide immediately before administration for PET imaging of PSMA-positive prostate cancer lesions. Distinctive features of the kit include a ready-to-use preparation format, disease-specific targeting, rapid imaging capabilities, and compatibility with theranostic workflows, which facilitates improved detection of metastatic lesions, comprehensive treatment planning, and effective monitoring of therapy response. Its applications involve diagnosing recurrent or metastatic prostate cancer and guiding personalized treatment decisions, marking a substantial progression over conventional imaging or non-targeted therapies.

Who Are The Established Players Within The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

Major companies operating in the prostate-specific membrane antigen (psma) theranostic kits market are Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, AdvanCell Pty Ltd, Alpha-9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, RadioMedix Inc., Scintomics GmbH, Novartis AG, Bayer AG, POINT Biopharma Inc., Blue Earth Diagnostics

Get The Full Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report:

https://www.thebusinessresearchcompany.com/report/global-prostate-specific-membrane-antigen-psma-theranostic-kits-market-report

Which Region Accounts For The Largest Portion Of The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

North America was the largest region in the prostate-specific membrane antigen (PSMA) theranostic kits market in 2025. The regions covered in the prostate-specific membrane antigen (psma) theranostic kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/global-prostate-specific-membrane-antigen-psma-theranostic-kits-market-report

Browse Through More Reports Similar to the Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market 2026, By The Business Research Company

Prostate Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Endocrine Peptide Test Market Report

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Expected To Change Between 2026 And 2030?

The market size for prostate-specific membrane antigen (psma) theranostic kits has experienced significant expansion recently. This market is projected to expand from $1.05 billion in 2025 to $1.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.9%. Historically, this growth has been driven by factors such as the rising incidence of prostate cancer, advancements in nuclear medicine imaging, increasing adoption of molecular diagnostics, early clinical validation of psma targeting, and the expansion of oncology research programs.

The prostate-specific membrane antigen (psma) theranostic kits market is anticipated to undergo significant expansion in the coming years. It is forecast to achieve a valuation of $1.99 billion in 2030, expanding at a compound annual growth rate (CAGR) of 13.5%. The projected surge during this period is primarily driven by an increasing need for tailored cancer treatments, growing investments in theranostics, the expansion of nuclear medicine infrastructure, the rising application of precision oncology diagnostics, and more frequent regulatory approvals for targeted therapies. Noteworthy trends for the forecast period include the increasing adoption of targeted radioligand therapies, the growing use of psma-based precision diagnostics, enhanced integration of imaging and therapy workflows, the expansion of personalized oncology treatment kits, and a sharpened focus on companion diagnostics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30362&type=smp

Which Economic Or Industry Drivers Are Impacting The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

The increasing occurrence of prostate cancer is anticipated to fuel the expansion of the prostate-specific membrane antigen (PSMA) theranostic kits market in the future. Prostate cancer is defined as a malignancy originating in the prostate gland, which is a small gland situated in men beneath the bladder and before the rectum. The increasing frequency of prostate cancer can be attributed to the aging demographic, given that the likelihood of developing this cancer rises considerably with advancing age. Prostate-specific membrane antigen (PSMA) theranostic kits improve the management of prostate cancer through the provision of targeted diagnostic tools, proving highly suitable for prompt diagnosis and customized therapeutic strategies. These kits boost diagnostic precision by integrating PSMA-specific ligands with radiotracers, thereby aiding in more effective disease surveillance and treatment direction. For example, reports from November 2023 by the American Cancer Society, a US-based non-profit organization, projected around 313,780 new cases of prostate cancer and 35,770 deaths in the United States by 2025. Consequently, the growing incidence of prostate cancer serves as a key impetus for the expansion of the prostate-specific membrane antigen (PSMA) theranostic kits market.

How Is The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Structured Across Different Segments?

The prostate-specific membrane antigen (psma) theranostic kits market covered in this report is segmented –

1) By Product Type: Diagnostic Kits, Therapeutic Kits, Combined Theranostic Kits

2) By Application: Prostate Cancer, Other Cancers

3) By End-User: Hospitals, Diagnostic Centers, Research Institutes, Specialty Clinics, Other End-Users

Subsegments:

1) By Diagnostic Kits: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography Imaging Kits, Single Photon Emission Computed Tomography Imaging Kits, Companion Diagnostic Kits, Liquid Biopsy Kits

2) By Therapeutic Kits: Radioligand Therapy Kits, Antibody-Based Therapy Kits, Peptide-Based Therapy Kits, Small Molecule Therapy Kits

3) By Combined Theranostic Kits: Integrated Imaging And Therapy Kits, Dual Function Radiopharmaceutical Kits, Prostate-Specific Membrane Antigen (PSMA) Ligand-Based Theranostic Kits, Personalized Treatment Kits

What Industry Trends Are Redefining The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

Companies operating in the prostate-specific membrane antigen (PSMA) theranostic kits market are prioritizing the creation of innovative solutions, such as PSMA-targeted radioligand kits, to satisfy the growing demand for precision oncology, precise prostate cancer diagnosis, and therapy. PSMA-targeted radioligand kits are medical supplies that combine a ligand specifically designed to bond with Prostate-Specific Membrane Antigen (PSMA) and a radioactive isotope for either diagnostic imaging or targeted therapy of prostate cancer. For example, in March 2025, Telix Pharmaceuticals Limited, an Australia-based radiopharmaceutical company, launched Illuccix, an advanced kit intended for the preparation of Gallium-68 gozetotide injection. This kit allows hospitals and nuclear medicine facilities to label the radionuclide immediately prior to injection for PET imaging of PSMA-positive prostate cancer lesions. The kit features a ready-to-use preparation format, disease-specific targeting, quick imaging capabilities, and compatibility with theranostic workflows, facilitating improved detection of metastatic lesions, treatment planning, and monitoring of therapy response. Its applications include the diagnosis of recurrent or metastatic prostate cancer and informing personalized treatment decisions, marking a significant improvement over conventional imaging or non-targeted therapies.

Which Major Players Dominate The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

Major companies operating in the prostate-specific membrane antigen (psma) theranostic kits market are Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, AdvanCell Pty Ltd, Alpha‑9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, RadioMedix Inc., Scintomics GmbH, Novartis AG, Bayer AG, POINT Biopharma Inc., Blue Earth Diagnostics

Read the full prostate-specific membrane antigen (psma) theranostic kits market report here:

https://www.thebusinessresearchcompany.com/report/global-prostate-specific-membrane-antigen-psma-theranostic-kits-market-report

What Are The Top-Performing Regions Within The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

North America was the largest region in the prostate-specific membrane antigen (PSMA) theranostic kits market in 2025. The regions covered in the prostate-specific membrane antigen (psma) theranostic kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30362&type=smp

Browse Through More Reports Similar to the Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market 2026, By The Business Research Company

Prostate Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Endocrine Peptide Test Global Market Report

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model